Last year, the Trump administration essentially disbanded the National Vaccine Program Office, folding it into an office focused on infectious diseases. Then the COVID-19 pandemic hit. What does this mean for monitoring the safety of the soon-to-be-approved COVID-19 vaccines?
The ethics of pay-to-play clinical trials are a minefield. Last week the HHS Secretary’s Advisory Committee on Human Research Protections (SACHRP) stepped into that minefield. Are “pay-to-play” clinical trials ever ethically acceptable?